Notoginsenoside R1 Ameliorates Cardiac Lipotoxicity Through AMPK Signaling Pathway

Xue Tian1, Xu Chen2, Qianqian Jiang1

  • 1School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.

Insights

Notoginsenoside R1 (NGR1) improves heart function in heart failure (HF) by reducing cardiac lipotoxicity. This protection is achieved through activating the Adenosine 5'monophosphate-activated protein kinase (AMPK) pathway, enhancing fatty acid oxidation, and inhibiting harmful lipid synthesis.

Area of Science:

  • Cardiovascular Biology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Cardiac lipotoxicity, stemming from lipid metabolism disorders, is a key factor in heart failure (HF) development.
  • Adenosine 5'monophosphate-activated protein kinase (AMPK) is an energy sensor with known beneficial effects in mitigating lipotoxicity.
  • Notoginsenoside R1 (NGR1), derived from Panax notoginseng, exhibits cardioprotective properties, but its role in mitigating HF via lipotoxicity was unexplored.

Purpose of the Study:

  • To investigate the potential protective role of NGR1 against heart failure (HF).
  • To determine if NGR1 ameliorates cardiac lipotoxicity.
  • To elucidate the underlying mechanism involving the Adenosine 5'monophosphate-activated protein kinase (AMPK) pathway.

Main Methods:

  • Established HF in mice using left anterior descending (LAD) ligation; treated with NGR1 or simvastatin.
  • Utilized palmitic acid (PA)-stimulated H9C2 cells to model cardiac lipotoxicity and assess NGR1 effects.
  • Evaluated cardiac function via echocardiography, measured lipid levels (ELISA), and analyzed protein expression (Western blot) for AMPK pathway and lipotoxicity markers. Assessed cell viability (CCK-8), lipid accumulation (LipidTOX™), and apoptosis (Hoechst/PI staining) in vitro.

Main Results:

  • NGR1 significantly improved cardiac function and reduced myocardial injury in HF mice, concurrently up-regulating p-AMPK expression.
  • NGR1 inhibited diacylglycerol (DAG) and ceramide synthesis while promoting fatty acid oxidation (FAO) by up-regulating CPT-1A and down-regulating GPAT and SPT.
  • In vitro, NGR1 attenuated PA-induced lipid accumulation and apoptosis in H9C2 cells; these effects were reversed by an AMPK inhibitor, confirming pathway involvement.

Conclusions:

  • Notoginsenoside R1 (NGR1) demonstrates significant efficacy in improving heart function and reducing cardiac lipotoxicity in a heart failure (HF) model.
  • The cardioprotective effects of NGR1 are mediated through the activation of the Adenosine 5'monophosphate-activated protein kinase (AMPK) pathway.
  • NGR1 modulates lipid metabolism by promoting fatty acid oxidation and inhibiting de novo lipogenesis, offering a potential therapeutic strategy for HF.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
772
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
540